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The antibacterial activity of some antimicrobials may be under-estimated during
in vitro microbiological susceptibility tests, due to their instability under such
conditions. The in vitro degradation of seven widely used antimicrobials (amoxicillin,
cephalexin monohydrate, cefotaxime sodium salt, ciprofloxacin, erythromycin hydrate,
clarithromycin, and doxycycline hyclate) and its effect on MIC and MBC determinations
was studied using the broth microdilution method, considered as the gold standard for
MIC determinations. In vitro concentrations of antimicrobials, over a 24 h incubation
period in the medium tested without bacteria, decreased from 33% for ciprofloxacin
to 69% for clarithromycin. For cephalexin, cefotaxime, clarithromycin, and doxycycline
which were the most degraded drugs, MIC and MBC values for one strain of E. coli
and one strain of S. aureus were compared using the standard method or after ad-hoc
drug complementation aiming at maintaining constant drug concentration. Abiotic
degradation during the standard method was associated with a significant increase of
the MIC (2 antibiotics) and MBC (3 antibiotics). However, the observed discrepancy (less
than one twofold dilution), even for the most degraded drug for which the concentration
at 24 h was reduced by two thirds, suggests that this would only be clinically significant
in special cases such as slow-growing bacteria.
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INTRODUCTION
The minimal inhibitory concentration (MIC) is the lowest concentration of an antimicrobial that
inhibits visible growth of a bacterial culture under a defined set of experimental conditions (Clinical
and Laboratory Standards Institute, 2012). One reference method for measuring MIC is broth
microdilution under standardized in vitro conditions, using a microdilution tray with twofold
drug-dilution steps, and subsequent visual evaluation of bacterial growth or non-growth after
16–20 h of culture at 35 ± 2◦C (Clinical and Laboratory Standards Institute, 2012). It is assumed
that the in vitro concentration of the tested antimicrobial remains unchanged throughout the
incubation period. However, the in vitro stability of antimicrobials is known to be affected by
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physical factors such as light, composition of the medium, pH,
and temperature (Paesen et al., 1994). Such instability may lead
to underestimation of the antibacterial activity of the compound
in Antimicrobial Susceptibility Tests (AST) (Marchbanks et al.,
1987) and thus alter the clinical decision to increase the dose, add
another antimicrobial agent, or even abandon therapy with the
compound. It has already been shown that the storage conditions
of prepared MIC trays can reduce the biological activity of
antimicrobials, depending on the drug, storage duration and
temperature (Barry et al., 1976; Nickolai et al., 1985; Hwang
et al., 1986; White et al., 1991). Few studies have focused on
the degradation of antimicrobials during the actual incubation
period (Wick, 1964; Marchbanks et al., 1987) and we are
not aware of any study of the subsequent effect on minimal
bactericidal concentration (MBC) determinations.
The aim of this study was to see if the incubation conditions
used during the microdilution test could lead to the substantial
degradation of some antimicrobials and if such degradation
could affect the AST results.
MATERIALS AND METHODS
Antimicrobial Degradation Experiment
The tested drugs were selected among antimicrobials frequently
used in human and veterinary medicine, without regard to
their reported stability status. The drugs and dilutions in the
microplates were as follows: Cephalexin monohydrate 0.5–
256µg/mL, amoxicillin 0.25–128µg/mL, cefotaxime sodium salt
0.125–64µg/mL, ciprofloxacin 0.031–16µg/mL, erythromycin
hydrate and clarithromycin 0.016–8µg/mL and doxycycline
hyclate 0.008–4 µg/mL. All drugs were tested at twofold serial
dilutions. The antimicrobial agents were dissolved according to
the specifications of the manufacturers (Sigma Aldrich, Saint
Louis, MO for amoxicillin, cefotaxime sodium salt, ciprofloxacin,
doxycyline hyclate, erythromycin hydrate and clarithromycin;
ACS Dobfar, Tribiano, Italy for cephalexin monohydrate).
Microdilution trays were prepared extemporaneously as
previously described for MIC determination (Nickolai et al.,
1985), except that 100µL of cation-adjusted, organism-free
Mueller-Hinton broth (MHB) was added to prevent any drug
degradation that might be caused by bacteria. The trays were
placed in a dark incubator at 37◦C. At each sampling time (i.e.,
0, 3, 6, 10, and 24 h), 100µL were collected from 3 adjacent wells
within less than 2 min, diluted with 900µL of H2O and stored at
4◦C for less than 4 h before analysis.
Antimicrobials Quantitative Analysis
All antimicrobials were assayed in triplicate by LC/MS with
an Acquity UPLC coupled to a Xevo triple quadrupole mass
spectrometer (Waters, Milford, MA, USA). Five microliters
of diluted sample were injected into a Cortecs C18 column
(2.1∗50mm; 1.6µm, Waters) and eluted with an H2O, 0.1%
formic acid and acetonitrile gradient (except for cephalexin
which was assayed with an H2O, 0.1% formic acid/acétonitrile
isocratic elution). The column and autosampler temperatures
were set at 40 and 10◦C respectively. Samples were ionized
in positive electrospray ionization mode (ESI+). The capillary
voltage and source temperature were set at 2.5 kV and 150◦C
respectively. The desolvation temperature and nitrogen flow
rate were set at 650◦C and 800 L/h respectively. Argon was
used as the collision gas at a flow rate of 0.12mL/min.
Quantification was by multiple reactions monitoring (MRM).
The MRM transitions, cone voltage and collision energies used
for the different antimicrobials are reported in Table 1. The
method was validated in terms of linearity, inter-day and intra-
day repeatability, selectivity and sensitivity, for each molecule
(ICH, 1994). The calibration curve was obtained by injecting
3 replicates of seven calibration standards prepared in MHB
and ranging from 0.01 to 50µg/mL. Three different approaches
were used to determine the linearity of the calibration curve: (1)
calculation of the relative concentration residuals between the
nominal concentration and the concentration obtained with the
model (RCR%), (2) visual inspection of the residual distribution,
and (3) application of a lack of fit test to check the goodness-of-fit
of the model (Almeida et al., 2002). The selectivity of the method
was characterized by injecting 6 replicates of MHB blank samples
and comparing the obtained signal with those obtained at the
limit of quantification (LOQ). The LOQ of each antimicrobial
was the lowest concentration on the calibration curve that could
be quantified with a precision lower than 20% and within an
accuracy range of 80–120%. Calculations of intra-day and inter-
day precisions and accuracies for each antimicrobial were based
on three different days (except for cephalexin: 2 days) and
with six replicates of QC samples at three concentration levels
(low, middle, and high) covering the range of standard curve
concentrations.
Effect of Antimicrobial Degradation on AST
The effects of antimicrobial degradation on AST were further
investigated by using the standard microdilution technique
(Clinical and Laboratory Standards Institute, 2012) with or
without an ad-hoc compensatory addition of antimicrobials
TABLE 1 | Retention times, MRM transitions, and MS parameters of seven
different antimicrobials.
Antimicrobials Retention
time
(min)
Ion
parent
(m/z)
Ion
daughter
(m/z)
Cone
voltage
(V)
Collision
energy
(eV)
Amoxicillin 0.81 366.0 349.1 14 8
113.9 22
Cefotaxime 1.49 456.0 396.1 18 12
166.9 20
Ciprofloxacin 1.49 332.1 288.1 32 18
245.1 24
Doxycycline 2.27 445.1 428.2 24 18
154.0 30
Erythromycin 2.94 734.4 158.1 26 30
576.4 20
Clarithromycin 3.5 748.5 158.1 30 30
82.9 46
Cephalexin 3.43 348.0 158.0 14 8
174.0 14
Frontiers in Microbiology | www.frontiersin.org 2 December 2016 | Volume 7 | Article 2051
Lallemand et al. Antimicrobials Stability and MIC Determination
at 6, 12, and 18 h. Cephalexin, cefotaxime, clarithromycin,
and doxycycline were selected for this purpose as they were
more extensively degraded than the other drugs tested. The
amount of antimicrobial degraded during each 6 h step was
calculated for each antimicrobial and each well. The computed
lost amounts were added in 5 µL to each 200 µL well, designated
“fortified well,” at each corresponding time in an attempt to
compensate for this degradation. Escherichia coli ATCC 25922
and Staphylococcus aureus HG001 strains were used as test
organisms. The MBC (Marchbanks et al., 1987; Clinical and
Laboratory Standards Institute, 1999) for each organism was
assessed by counting the viable bacteria in the broth from all
wells that inhibited visible growth at 24 h. Bacteria were counted
in triplicate on tryptic soy agar supplemented with magnesium
sulfate and activated charcoal to prevent antibiotic carry-over
effects. Colonies were counted after overnight incubation at
37◦C. The lowest concentration of the antimicrobial that killed
≥99.9% of the initial inoculum was defined as the MBC end
point. MBC and MIC were determined in triplicate at 24 h and
the values for the control and fortified wells were compared by
Wilcoxon test, with statistical significance set at p ≤ 0.05.
RESULTS
Analytical Results
The UPLC conditions were optimized to ensure the rapid elution
of all 7 antimicrobials with reliable retention times and MS
ionizations to avoid storage in the autosampler. The elution
was performed on a C18 column within 5 min and detection
was by MRM in positive electrospray ionization (ESI+). All
7 antimicrobials gave the protonated parent [M+H]+ with
two MRM transitions. The MRM transition with the highest
intensity was selected for quantification and the second MRM
transition was used for antimicrobial confirmation. These two
MRM transitions, the precise time of retention, in addition to the
absence of interference in the MHB blank samples corroborated
the high selectivity of the method.
Calibration ranges were chosen to include the MIC most
frequently reported by EUCAST for Staphylococcus aureus
strains. They also included the reported ECOFF values for
S. aureus strains, except for amoxicillin for which the E. coli
ECOFF value was chosen as no data for S. aureus were available
(EUCAST, 2016). The LOQ was established in order to be able
to quantify at least 90% of antimicrobial degradation (except for
doxycycline). The validation results are reported in Table 2. The
accuracy for all 7 antimicrobials ranged from 92 to 111% with a
precision of less than 18%. LOQ were validated at 0.01µg/mL for
cefotaxime, ciprofloxacin and the two macrolides clarithromycin
and erythromycin, at 0.05µg/mL for amoxicillin and doxycycline
and at 0.1µg/mL for cephalexin. The accuracy at the LOQ ranged
from 80 to 120% with a precision lower than 18%.
Degradation of Different Antibiotics during
the Broth Microdilution Test
The concentrations tested were 2, 4, and 8µg/mL for amoxicillin
(Figure S1) and cephalexin, 1, 2, and 4µg/mL for cefotaxime,
0.25, 0.5, and 1µg/mL for ciprofloxacin, 0.125, 0.25, and
0.5 µg/mL for erythromycin and clarithromycin and 0.0625,
0.125, and 0.25 for doxycycline. The degradation half-lives and
percentages of degradation of the seven antimicrobials, measured
after incubation for 24 h using the standard broth microdilution
test conditions, are given in Table 3. All these drugs were
unstable (degradation > 20%) at the above concentrations and
conditions. Some drugs, such as clarithromycin and doxycycline
hyclate, were highly degraded (more than 60%). Others, such
as amoxicillin, cephalexin monohydrate, cefotaxime sodium salt
and erythromycin hydrate were moderately degraded (from 40
to 60%) while ciprofloxacin showed the least degradation (less
than 40%).
Consequences of Antibiotic Degradation
on MIC and MBC Determinations
The MBC and MIC values for each test organism and each drug
are given in Table 4. The MIC and MBC values obtained in the
fortified wells were either equal to or lower than those obtained
under standard conditions (no compensation for drug lost). The
AST values were significantly different for one drug out of 4 for
each investigated organism. However, the differences, unrelated
to the presence of microorganisms, never exceeded more than
one dilution.
DISCUSSION
The stability or instability of the different antimicrobials used
in our study has already been reported in various liquid and
solid media (Hwang et al., 1986; Marchbanks et al., 1987;
Paesen et al., 1994; Erah et al., 1997). Erah et al. showed that
amoxicillin and clarithromycin are stable at pH 7 in aqueous
solution with a degradation half-life of respectively 153.1 h
and undetectable degradation (Erah et al., 1997). However,
the stability of a given drug in one set of conditions cannot
be univocally extrapolated to other conditions. Indeed, in
our experiment, the degradation half-lives of amoxicillin and
clarithromycin inMHB at 37◦Cwere 27.4 and 14.2 h respectively.
Cefotaxime stability in solution at 24 h is reported to be 92%
at 25◦C and 72% at 45◦C (Behin et al., 2012). The extent of
degradation inMHB is greater as 44.7% of the drug was degraded
at 24 h and 37◦C. While it is clear that light, temperature,
and pH are important factors to consider, the test medium
can also influence stability of a compound (Paesen et al.,
1994). Cielecka-Piontek et al. did study the effect of different
injection media on stability of meropenem and clavulanate
potassium in order to allow clinical administration of both
compound together while maximizing stability and compatibility
(Cielecka-Piontek et al., 2015). There were clear differences
between media, indicating the use of one media more than
others in a clinical setting even if all of them where aqueous.
Differences between media can be explained by their nature
(aqueous or lipophilic) or differences in the catalytic effects
of degradation products(Cielecka-Piontek et al., 2015). Wick
stated in 1964 that every new antibiotic should be subjected
to a complete study of stability under test conditions (Wick,
1964).
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TABLE 2 | Validation results for seven different antimicrobials in MHB.
Antimicrobials Linearity (n = 3) Sensitivity (n = 6) Repeatability (n = 6, 3 days)
Calibration
range (µg/mL)
Model
weighting
LOQ
(µg/mL)
Accuracy % CV % QC (µg/mL) Accuracy % CV intra-day % CV inter-day %
Amoxicillin 0.05–10 Linear 1/X 0.05 90 17 0.075 102 14 17
0.25 94 9 11
2.5 98 4 7
Cefotaxime 0.01–10 Linear 1/X2 0.01 115 12 0.025 96 18 16
0.25 92 9 9
2.5 104 5 9
Ciprofloxacin 0.01–10 Linear 1/X 0.01 120 18 0.025 102 17 15
0.25 95 4 10
2.5 100 7 8
Doxycycline 0.05–10 Linear 1/X 0.05 80 9 0.075 97 8 14
0.25 97 4 7
2.5 104 8 8
Erythromycin 0.01–10 Quadratic 1/X 0.01 111 9 0.025 111 3 7
0.25 97 2 4
2.5 98 8 10
Clarithromycin 0.01–10 Quadratic 1/X 0.01 116 8 0.025 106 4 18
0.25 101 4 14
2.5 103 10 17
Cephalexin* 0.1–50 Linear 1/X2 0.1 109 9 0.3 98 8 8
2 100 9 10
15 104 9 9
*Cephalexin was assayed with a previous existing method and repeatability was evaluated on 2 days.
TABLE 3 | Half-lives and percentages of degradation after 24h for
different antimicrobials under the same conditions as in the MIC
determination, apart from the absence of bacteria.
Antimicrobial Degradation
half-life (h)*
Percentage of degradation
after 24h (%)
Amoxicillin 27.4 45.5
Cefotaxime 28.1 44.7
Ciprofloxacin 42.0 32.7
Doxycycline 16.9 62.6
Erythromycin 31.5 41.0
Clarithromycin 14.2 69.0
Cephalexin 20.2 56.1
*Half-life was estimated using a monoexponential model to describe the observed decay.
The means of 3 experiments are reported.
Previous studies have shown that antimicrobials can
be degraded during the storage of MIC trays depending
on the selected drug and storage time and that a low
temperature (−70◦C) is usually best for storage (Barry
et al., 1976; Hwang et al., 1986; Marshall et al., 2000).
Problems with imipenem stability have been reported
during storage of MIC trays (Nickolai et al., 1985), but it
did not occured with meropenem in the same conditions
(Dowzicky et al., 1994) despite also being a carbapenem,
attesting the need to study each compound in a given
condition. It also highlighted that every precaution should
be taken to minimize the loss of moisture from the frozen
trays (Barry et al., 1976). White et al. demonstrated that
antimicrobial degradation during storage can also result
in a decline of susceptibility as the MIC values increase
with degradation and storage time (White et al., 1991). Our
results confirmed that antimicrobial degradation during
incubation can lead to a significant increase in the observed
MIC or MBC values and hence to a bias when reporting AST
results.
AST plays a major role in predicting the efficacy of an
antibiotic against clinical pathogens and thus in its subsequent
selection (Craig, 1998). As our study with the standard
microdilution method showed that some widely-used antibiotics
were degraded during incubation, we explored the possible
consequences of a biased MIC estimate on AST interpretation.
AST results are assigned to one of three categories (susceptible,
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TABLE 4 | MIC and MBC data for 4 unstable antimicrobials against Escherichia coli and Staphylococcus aureus at 24h with the standard microdilution
method or with ad-hoc addition of antimicrobial every 6h to compensate for degradation.
Organism tested and drug Mean MIC (µg/mL) [Interval] Mean MBC (µg/mL) [Interval] No. of replicates
Standard
microdilution
With addition of
drug
Standard
microdilution
With addition of
drug
E. coli
Cephalexin 10.67 [8-16] 8 [8] NS 12 [8-16] 8 [8] NS 6
Cefotaxime 0.058
[0.031–0.063]
0.045
[0.031–0.063]
NS 0.071
[0.063–0.125]
0.049
[0.031–0.063]
P ≤ 0.05 7
Clarithromycin 32 [32] 32 [32] NS 128 [128] 128 [128] NS 4
Doxycycline 1.125 [0.5–2] 0.625 [0.5–1] P ≤ 0.05 >16 [>16] >16 [>16] NS 8
S. aureus
Cephalexin 5.5 [2–8] 4.5 [2–8] NS 12 [8–16] 7 [4–8] P ≤ 0.05 4
Cefotaxime 2 [2] 1.5 [1–2] P ≤ 0.05 3.66 [2–4] 2.33 [2–4] P ≤ 0.05 6
Clarithromycin 0.125 [0.125] 0.125 [0.125] NS 0.25 [0.25] 0.25 [0.25] NS 2
Doxycycline 0.031 [0.031] 0.031 [0.031] NS 0.088
[0.063-0.125]
0.063 [0.063] NS 5
Groups significantly different (p ≤ 0.05) or not (NS).
intermediate, or resistant) based on two critical lower and
upper MIC breakpoints. The susceptible and resistant classes
are commonly separated by an intermediate class corresponding
to just one twofold dilution (Annis and Craig, 2005). Given
the narrowness of this intermediate range, such a factor of
variability can seriously impact the correct classification of a
pathogen if its MIC is near the breakpoints (Craig, 2000).
PK/PD indices such as AUC/MIC are used to establish optimal
dosing regimens and are calculated from the MIC reported
for the pathogen (Craig, 1998). The impact of an incorrect
MIC on the dosage regimen calculation can thus be very
real.
Nevertheless, it has to be kept in mind that, in our study,
the differences in MIC or MBC values due to antimicrobial
degradation was never higher than one twofold dilution even if
69% degradation of clarithromycin could have suggested a higher
impact on MIC and MBC values. This small effect on AST values
could be related to the short bacterial generation times, which
are 25 and 29 min, respectively, for our strains of E. coli and
S. aureus in MHB (personal data), compared to antimicrobial
degradation half-lives that are quite long in comparison to
those doubling times in our study. Furthermore, a MIC value
is not a simple concentration, unlike the value measured
by HPLC, and actually represents the overall effect obtained
over the entire incubation time. Repeated measurements of
MIC using the same pathogen/drug combination commonly
show a 3-fold dilution range, meaning that the standard
microdilution method has an accuracy of not less than one
dilution interval and that a one dilution difference can be
considered as acceptable (Wexler et al., 1990; Annis and Craig,
2005).
In some specific situations requiring accurate MIC and
MBC values, or when the bacterial doubling time is higher
than the drug half-life, as with Mycobacterium tuberculosis
(Srivastava et al., 2016), accurate data may be obtained by
controlling the antimicrobial concentration to balance antibiotic
degradation. Srivastava et al. recently described a method
for measuring the MIC of ertapenem against M. tuberculosis
(Srivastava et al., 2016). They used tubes with bacteria and
different concentrations of antimicrobial and added a daily
supplement to compensate for ertapenem degradation. The
resulting MIC was far lower than the MIC obtained with non-
compensated tubes (0.6 and mg/L respectively). Another option
is to plot bactericidal time-kill curves by using an initial bacterial
inoculum of 5 105 UFC/mL and varying the concentrations of
antimicrobial. The interaction between the antimicrobial and
the bacteria can be modeled (Nielsen and Friberg, 2013) and
drug degradation could be considered in the modeling process
(Nielsen and Friberg, 2013). The MIC obtained with this method
would correspond to the concentration of antimicrobial for
which a final inoculum of 5 105 UFC/mL is obtained at 20
or 24 h. Such methods are interesting for specific cases but
are time-consuming and cannot be applied to standard MIC
determinations. In this study, we only considered the possible
action of an abiotic MHB culture medium on antimicrobial
degradation, as measured by UPLC, using the strict conditions
applied during microdilution testing. Antibiotic degradation
during such testing can also be due to metabolism, as with
serum esterases and cefotaxime, for example, (Marchbanks
et al., 1987), or to the effect of microorganisms in the
system (Wick, 1964). Another potential source of variation for
MIC determination can be the cation concentration variability
in Mueller-Hinton broth (Clinical and Laboratory Standards
Institute, 1999). This problem was overcome in our study by
using the same cation-adjusted Mueller-Hinton broth for all
experiments.
On the basis of our results, we conclude that the microdilution
method remains suitable for testing the antimicrobial
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susceptibility of most common pathogens, despite the
concomitant degradation of some antimicrobials.
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